

# "Nanoplatforms based on plasmonic nanoparticles for multitherapy in the treatment of cancer"



L. Arellano<sup>1,\*</sup>,<sup>1</sup> B. Velasco<sup>1</sup>, V. Figueroa<sup>1</sup>, E. Villar<sup>1</sup>, A. Cambón<sup>1</sup>, A. A. Almodlej<sup>2</sup>, S. Barbosa<sup>1</sup>, P. Taboada<sup>1</sup>

Grupo de Física de Coloides y Polímeros, Departamento de Física de la Materia Condensada, Facultad de Física, Universidad de Santiago de Compostela, E-15782. Santiago de Compostela (Spain). \*liliagarellanog@gmail.com

. INTRODUCTION

METODOLOGY

In most of the cases, the diagnostic and therapy stages are carried out independently and this lead to delays in the application of the treatments and, therefore, an important risk to the patients' health. To overcome these incoveniences, in the few last years theranostic has reached an important role to join in a unique nanoplatform therapeutic treatment, action and monitoring of the response to simultaneous therapy.

Thus, we designed a hybrid nanosystems based on gold nanoparticles capable of simultaneously combining their potential as a photodynamic therapeutic agent (PDT), plasmonic photothermal therapy (PPTT) and/or chemotherapy to kill malignant cells [1-11].



- This indicates that we must improve the interaction between the nanoplatform and
- confocal microscope. This allows us to observe that there is an adequate internalization of the applied concentration  $(1 \times 1011 \text{ rods} / \text{mL})$ .
- Also, in pictures C and D, we observe the presence of the complete nanoplatform where it is observed to be located at the cytoplasm of the cell.

**IN VITRO STUDIES: BIOCOMPATIBILITY** 

NANOPLATFORMS-HELA CELLS

Acknowledgements: This work was supported by

Agencia Estatal de Investigación (AEI) through Project

80266-R, and Xunta de Galicia (Grupo de Referencia

Competitiva ED431C 2018/26; Agrupación Estratégica

en Materiales-AEMAT ED431E 2018/08). FEDER funds

- In the FT-IR spectrum we can verify by the vibrational modes of each functional group, the layers added by the layer by layer method.
- The irradiation at 1 and 2 W / cm2 shows that after irradiation with the laser of a wavelength of 808 nm, with an exposure time of 30 min, the morphology of the GNRs
- transverse and longitudinal plasmon bands of the GNRs continue in each layer.
- The plasmons bands continue in the biological windows. We can also observe that the size of the nanoplatform is between 89 and 97 nm.
- The morphology of the GNRs can be observed by SEM. We can verify that the

morphology of the GNRs continues to be maintained after each layer.

### **CHARACTERIZATION OF THE NANOPLATFORM: MORPHOLOGY, UV-VIS, ζ-POTENTIAL AND PARTICLE SIZE**

## **IV. CONCLUSIONS**

changes, which allows us to ensure the drug release. The increase in temperature confirms the presence of localized heat therapy.

**CHARACTERIZATION OF THE LAYER BY LAYER** 

**PROCESSS BY FTIR AND PPTT AND CHEMOTHERAPY** 

### • The GNRs were characterized with a suitable longitudinal and transversal plasmon band within the biological window after the layer by layer coating process.

- The applied layers were added by steric impediment, which allows the observation of the charge changes from anionic to cationic.
- After the layer by layer coating processes, the final size of the nanoplatform remains at the nanometer range.
- From FTIR-spectrum vibrational modes, each polyelectrolyte layer were identified.
- GNRs Irradiation tests proved the nanoplatforms photothermal therapy.
- The internalization of the GNRs in HeLa cells verify the biocompatibility of the nanoplatform.

#### **References:**

- 1. Tibbitt, M. W.; Dahlman, J. E.; Laner, R. J. Am. Chem. Soc. 2016, 138, 704.
- Lim, E.-K.; Kim, T.; Paik, S.; Haam, S.; huh, Y.-M. Lee, K. Chem. Rev. 2015, 115, 327.
- Marangoni, S. P.; Cancino-Bernardini, J.; Zucolotto, V. J. Biomed. Nanotecnol. 2016, 12, 1136.
- V.; Menon R. S.; Biju A. T.; Sinu C.R.; Paul R. R.; Jose A.; Sreekumar V. Chem. Soc. Rev. 2011, 40, 5336. Nair
- 5. N. R. Jana, L. Gearheart y C. J. Murphy, The Journal of Physical Chemistry, vol. 105, pp. 4065-4067, 2001.

- B. Nikoobakht y M. A. El-Sayed, Chemistry of Materials, vol. 15, n° 10, pp. 1957-1962, 2003. 6.
- M. Hu, J. Chen, L. Zhi-Yuan, L. Au, G. V. Hartland, L. Xingde, M. Marquez y X. Younan, Chemical Society Reviews, vol. 35, pp. 1084-1094, 2006.

MAT2016-

are also acknowledged.

- F. Ren, S. Bhana, D. D. Norman, J. Johnson, L. Xu, D. L. Baker, A. L. Parrill y X. Huang. Bioconjugate Chemistry, vol. 24, n° 3, pp. 376-386, 2013.
- S. Amorim, A. Martins, N. M. Neves, R. L. Reis y R. A. Pires, Journal of Materials Chemistry B, vol. 2, n° 40, pp. 6939-6946, 2014.
- 10. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu y . M. J. Thun, Cancer Journal of Clinicians, vol. 59, n° 4, pp. 225-249, 2009.
- 11. X. Huang y M. A. El-Sayed. Alexandria Journal of Medicine, vol. 47, n° 1, pp. 1-9, 2011.